Pro-gastrin-releasing peptide (serum)

General Information

Pro-gastrin-releasing peptide is a precursor of the gut hormone gastrin-releasing peptide.

Elevated titers of pro-gastrin-releasing peptide have been found in small cell lung cancer. The research is characterized by high sensitivity and specificity for the mentioned tumor, and its concentration correlates with the progression of the tumor process.

Clinical information 

Clinical studies have established that pro-gastrin-releasing peptide and neuron-specific of enolase It has additional diagnostic value in small cell lung cancer. Neuron-specific enolase index has a prognostic value for this tumor.

4 markers -  Carcinoembryonic antigen CEA, ცItokeratin fragment19 CYFRA 21-1, Neuron-specific enolase და of pro-gastrin-releasing peptide  Diagnostic value in lung tumors of unknown origin. The specificity of pro-gastrin-releasing peptide exceeded >99% as a high-performance diagnostic index. The carcinoembryonic marker showed the highest possibility of detecting the malignant process. The CYFRA 21-1 marker was found to be specific mainly in epithelial cell tumors of the lung.

When all four markers were combined, the positive predictive values ​​were: 50% for malignant lung tumors, 44% for non-small cell tumors, 36% for epithelial cell carcinomas, 53% for adenocarcinomas, and 78% for small cell lung tumors.

Therefore, in cases of lung tumors of unknown origin, the use of all four markers is very informative for differential diagnostics.

Patient care – no need

Research material - Venous blood

Referral norm – <30 ng/ml

In case of kidney failure, false-positive test results are common. Therefore, determination of pro-gastrin-releasing peptide is essential Kidney function tests Conducting.